cRY9M 是一种可结合 FGFR1 的环肽,其 KD 值为 58 nM,可特异性结合 FGFR1,体内稳定性增强,注射后在血液、尿液和肝匀浆中的降解程度极低,在 FGFR1 阳性肿瘤异种移植模型中表现出显著的特异性摄取,而在 FGFR1 阴性肿瘤模型和阻断模型中的摄取量降低,其 NOTA 螯合前体经 68Ga 标记后可得到 [68Ga]Ga-NOTA-cRY9M,用于非小细胞肺癌中 FGFR1 表达的无创显像研究。
cRY9M
产品编号: MS-C74249 分子式: C59H89N23O12 分子量: 1312.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

cRY9M 是一种可结合 FGFR1 的环肽,其 KD 值为 58 nM,可特异性结合 FGFR1,体内稳定性增强,注射后在血液、尿液和肝匀浆中的降解程度极低,在 FGFR1 阳性肿瘤异种移植模型中表现出显著的特异性摄取,而在 FGFR1 阴性肿瘤模型和阻断模型中的摄取量降低,其 NOTA 螯合前体经 68Ga 标记后可得到 [68Ga]Ga-NOTA-cRY9M,用于非小细胞肺癌中 FGFR1 表达的无创显像研究。

生物实验数据

生物活性 cRY9M is a cyclic peptide that binds FGFR1 with a KD of 58 nM, specifically binds FGFR1 with enhanced in vivo stability and minimal degradation in blood, urine, and liver homogenates after injection, exhibits significant specific uptake in FGFR1-positive tumor xenograft models while showing reduced uptake in FGFR1-negative tumor models and blocking models, and its NOTA-chelated precursor can be labeled with 68Ga to yield [68Ga]Ga-NOTA-cRY9M for non-invasive imaging of FGFR1 expression in non-small cell lung cancer.
体外研究
(In Vitro)

[68Ga]Ga-NOTA-cRY9M (4 h) 在 37 °C 的胎牛血清 (FBS) 中孵育 4 小时后仍保持 95% 以上的放射化学纯度。
[68Ga]Ga-NOTA-cRY9M (74 kBq; 15-120 min) 在 Calu-3、NCI-H520 和 NCI-H2170 细胞中呈现时间依赖性、FGFR1 特异性的细胞摄取。
[68Ga]Ga-NOTA-cRY9M (74 kBq; 2 h) 可抑制 FGFR1 与 Calu-3 细胞的结合,其 IC50 为 62 nM。

体内研究
(In Vivo)

[68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单剂量) 在 FGFR1 高表达的 NSCLC 异种移植模型中展现出更优的肿瘤靶向性,其肿瘤摄取峰值达 3.69 %ID/g,肿瘤与肌肉的最大比值为 5.56。
[68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单剂量) 靶向 FGFR1 中度表达的 NSCLC 异种移植物,其肿瘤摄取峰值达 3.11 %ID/g,肿瘤与肌肉的最大比值为 4.10。
68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单剂量) 在 FGFR1 低表达的 NSCLC 异种移植瘤中的摄取量极低,最大肿瘤摄取率为 1.20 %ID/g,且肿瘤与肌肉的比值较低。
NOTA-cRY9M (静脉注射;单剂量,提前 30 分钟,200 倍过量) 预处理可阻断 Calu-3 异种移植瘤中 [68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单剂量) 的 FGFR1 特异性摄取,使肿瘤最大摄取量降至 1.45 %ID/g。
[68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单次给药) 可特异性靶向 FGFR1 高表达的 NSCLC PDX 肿瘤,其肿瘤摄取峰值达 3.84 %ID/g,肿瘤与肌肉的最大比值为 5.28;过量未标记肽 (200 倍过量;静脉注射;单次给药,提前 30 分钟) 可阻断其摄取。
[68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单次给药) 在 NSCLC PDX 肿瘤中的摄取与 FGFR1 表达相关,在 PDX-M 肿瘤中呈现中等程度的聚集。
[68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单剂量) 在 FGFR1 低表达的 NSCLC PDX 肿瘤中摄取量极低,与靶标低表达的情况一致。
68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单剂量) 可特异性靶向 FGFR1 阳性乳腺癌异种移植瘤,其摄取水平与靶标表达相关。
[68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单次给药) 可特异性靶向 FGFR1 阳性胰腺癌异种移植瘤,其聚集水平与靶标表达量相关。
[68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单剂量) 在 FGFR1 低表达乳腺癌异种移植物中摄取量极低,与靶标低表达的情况一致。

Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of 5 million Calu-3 cells mixed with 50% Corning Matrigel, tumors grown to 200−300 mm3 over 1−2 weeks)
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Achieved peak tumor uptake of 3.69 %ID/g at 10 minutes postinjection, with gradual decline to 3.33 %ID/g by 60 minutes.
Exhibited primarily renal excretion with low hepatic retention.
Reached a maximum tumor-to-muscle ratio of 5.56 at 60 minutes, with tumor-to-liver and tumor-to-lung ratios of approximately 2.3 and 3.3, respectively, at 60 minutes.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of 5 million NCI-H520 cells mixed with 50% Corning Matrigel, tumors grown to 200−300 mm3 over 1−2 weeks)
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Achieved peak tumor uptake of 3.11 %ID/g at 10 minutes postinjection, with subsequent decline.
Reached a maximum tumor-to-muscle ratio of 4.10 at 60 minutes.
Showed tumor uptake of 2.61 %ID/g at 60 minutes postinjection via ex vivo biodistribution.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of 5 million NCI-H2170 cells mixed with 50% Corning Matrigel, tumors grown to 200−300 mm3 over 1−2 weeks)
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Reached a maximum tumor uptake of 1.20 %ID/g.
Maintained a consistently low tumor-to-muscle ratio of ~1.42 throughout the imaging window.
Showed tumor uptake of 0.91 %ID/g at 60 minutes postinjection via ex vivo biodistribution.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of 5 million Calu-3 cells mixed with 50% Corning Matrigel, tumors grown to 200−300 mm3 over 1−2 weeks, blocking study with unlabeled NOTA-cRY9M)
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M; 200-fold excess unlabeled NOTA-cRY9M
Administration: i.v.; single dose (tracer); i.v.; single dose (unlabeled peptide, 30 minutes prior to tracer)
Result: Reduced maximal tumor accumulation to 1.45 %ID/g at 60 minutes postinjection.
Reached a tumor-to-muscle ratio of only 1.77 at 60 minutes.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, patient-derived xenograft model PDX-H, established via subcutaneous implantation of 3 mm3 NSCLC patient tumor tissue into secondary BALB/c nude mice, tumors grown to appropriate size)
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M; 200-fold excess unlabeled NOTA-cRY9M (blocking study)
Administration: i.v.; single dose (tracer); i.v.; single dose (unlabeled peptide, 30 minutes prior to tracer, blocking study)
Result: Achieved peak tumor uptake of 3.84 %ID/g at 10 minutes postinjection.
Reached a maximum tumor-to-muscle ratio of 5.28.
Reduced tumor uptake to 1.28 %ID/g after pretreatment with unlabeled NOTA-cRY9M.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, patient-derived xenograft model PDX-M, established via subcutaneous implantation of 3 mm3 NSCLC patient tumor tissue into secondary BALB/c nude mice, tumors grown to appropriate size)
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Exhibited tumor uptake levels intermediate between PDX-H and PDX-L, with corresponding tumor-to-muscle ratios consistent with FGFR1 expression levels.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, patient-derived xenograft model PDX-L, established via subcutaneous implantation of 3 mm3 NSCLC patient tumor tissue into secondary BALB/c nude mice, tumors grown to appropriate size)
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Exhibited minimal tumor uptake, comparable to background levels.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of MDA-MB-231 cells mixed with 50% Corning Matrigel, tumors grown to appropriate size)
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Showed significant accumulation in MDA-MB-231 tumors (FGFR1-positive), correlating with FGFR1 expression levels.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of PANC-1 cells mixed with 50% Corning Matrigel, tumors grown to appropriate size)
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Showed significant accumulation in PANC-1 tumors (FGFR1-positive), correlating with FGFR1 expression levels.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of MDA-MB-468 cells mixed with 50% Corning Matrigel, tumors grown to appropriate size)
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Showed minimal accumulation in MDA-MB-468 tumors (FGFR1-low), correlating with low target expression.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of FGFR1-knockdown Calu-3 cells mixed with 50% Corning Matrigel, tumors grown to appropriate size)
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Exhibited substantial reduction in tracer uptake (1.10 %ID/g) in FGFR1-knockdown Calu-3 xenografts compared to control Calu-3 tumors (3.83 %ID/g).
Showed correspondingly lower tumor-to-muscle ratios (2.11 vs 5.89) in FGFR1-knockdown vs control tumors.

化学信息

分子量 1312.48
分子式 C59H89N23O12

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础